SCHEMBL4402910

SCHEMBL4402910

CCC1O[C@H](OCc2ccccc2)C(O[C@H]2OC(COC(=O)c3ccccc3)[C@@H](C)[C@H](C)C2OC(=O)c2ccccc2)[C@@H](C)[C@@H]1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGF2 P09038 4/20 0.41
▸ FGF1 P05230 3/20 0.41
▸ VEGFA P15692 3/20 0.41
▸ HPSE Q9Y251 3/20 0.41
▸ NT5E P21589 1/20 0.41
▸ KMT2A Q03164 3/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ PTPN1 P18031 2/20 0.37
▸ GAPDH P04406 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ ANTXR2 P58335 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SELP P16109 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4407362 0.97 FGF2 (0.40) FGF2FGF1VEGFAHPSENT5E
SCHEMBL4402915 0.95 FGF1 (0.39) FGF2FGF1VEGFAHPSENT5E
SCHEMBL4403642 0.92 FGF1 (0.38) FGF2FGF1VEGFAHPSENT5E
SCHEMBL15965619 0.87 TYMP (0.40) FGF2FGF1VEGFAHPSENT5E
SCHEMBL4403646 0.85 SLC6A2 (0.36) FGF2FGF1VEGFAHPSENT5E
SCHEMBL3700974 0.83 ANTXR2 (0.50) FGF2FGF1VEGFAHPSENT5E
SCHEMBL26562238 0.83 PAX8 (0.38) KMT2AMEN1USP2POLBPTPN1
SCHEMBL12920535 0.83 NT5E (0.54) FGF2FGF1VEGFAHPSENT5E
SCHEMBL14683530 0.83 LGALS3 (0.45) FGF2FGF1VEGFAHPSENT5E
SCHEMBL19036055 0.82 PTPN1 (0.50) NT5EKMT2AMEN1USP2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173606-B2 Sulfated oligosaccharide derivatives PROGEN PHARMACEUTICALS LIMITED (AU) 2012-05-08 — — US disclosed
US-20110130354-A1 SULFATED OLIGOSACCHARIDE DERIVATIVES PROGEN PHARMACEUTICALS LIMITED (AU) 2011-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130354-A1 SULFATED OLIGOSACCHARIDE DERIVATIVES HPSE, APOB, LIPG FGF2 166/4885FGF1 348/4885VEGFA 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback